Want to see SE:BIOEX full AI Analyst Report?

Bioextrax AB (BIOEX) Price & Analysis

0 Followers

BIOEX Stock Chart & Stats

kr3.19

kr0.10(3.70%)

At close: Mar 06 4:00 PM EST

kr3.19

kr0.10(3.70%)

Day’s Range― - ―

52-Week Rangekr1.60 - kr3.98

Previous CloseN/A

Volume15.49K

Average Volume (3M)82.14K

Market Cap

kr115.67M

Enterprise Valuekr117.21

Total Cash (Recent Filing)kr3.93M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta0.80

Next Earnings

Aug 21, 2026

EPS Estimate

-0.09

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.35

Shares Outstanding47,601,730

10 Day Avg. Volume104,394

30 Day Avg. Volume82,137

Financial Highlights & Ratios

PEG Ratio0.46

Price to Book (P/B)5.23

Price to Sales (P/S)146.53

P/FCF Ratio-4.23

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.37

Revenue Forecast (FY)kr2.34M

Bulls Say, Bears Say

Bulls Say

Conservative Balance SheetZero reported debt materially reduces refinancing and interest-rate risk for a capital-hungry biotech. This durable financial posture preserves strategic optionality to raise equity or structure partnerships for scale-up, giving management flexibility to prioritize R&D and commercialization over the coming months.

Sustainable, Scalable Business ModelThe company’s fermentation-based production of microbial biopolymers aligns with a secular shift toward sustainable, bio-based materials in food, cosmetics and industrials. This structural market tailwind supports a durable addressable market and the potential for scalable manufacturing and recurring product sales if commercialized.

Demonstrated Top-line Growth EpisodesA reported ~45% revenue growth metric shows the business can capture incremental demand and win customers in certain periods. While scale remains small, historic growth episodes indicate potential commercial traction that could translate into durable revenue expansion if unit economics and distribution are improved.

Bears Say

Persistent UnprofitabilityNegative gross profit and recurring deep net losses indicate the firm has not achieved positive unit economics. Over the medium term this erodes equity, prevents internal reinvestment, and means the company must materially improve margins or secure external funding to become self-sustaining.

Weak Cash Generation And Accelerating Cash BurnConsistent negative operating and free cash flows, with acceleration in 2025, create a structural financing need. This raises the likelihood of dilutive equity raises or dependency on partners, which can constrain strategic choices, delay projects and increase execution risk over the next several quarters.

Small, Volatile Revenue BaseA very small and volatile revenue base limits the company’s ability to absorb fixed costs and achieve margin stability. Declines in recent years heighten execution risk and make multi-quarter planning difficult, increasing dependence on sporadic contract income or external capital to sustain operations.

Bioextrax AB News

85X0 Earnings this Week: How Will it Perform?

Bioextrax AB (85X0) is scheduled to report 1st quarter earnings on 05/14/2026. Regarding Q1 estimates, Wall Street analysts...

3M ago

Is 85X0 a Buy, Before Earnings?

Bioextrax AB (85X0) is scheduled to report 4th quarter earnings on 02/19/2026. Regarding Q4 estimates, Wall Street analysts...

6M ago

BIOEX FAQ

What was Bioextrax AB’s price range in the past 12 months?

Bioextrax AB lowest stock price was kr1.60 and its highest was kr3.98 in the past 12 months.

What is Bioextrax AB’s market cap?

Bioextrax AB’s market cap is kr115.67M.

When is Bioextrax AB’s upcoming earnings report date?

Bioextrax AB’s upcoming earnings report date is Aug 21, 2026 which is in 19 days.

How were Bioextrax AB’s earnings last quarter?

Bioextrax AB released its earnings results on May 20, 2026. The company reported -kr0.09 earnings per share for the quarter, beating the consensus estimate of -kr0.1 by kr0.01.

Is Bioextrax AB overvalued?

According to Wall Street analysts Bioextrax AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Bioextrax AB pay dividends?

Bioextrax AB does not currently pay dividends.

What is Bioextrax AB’s EPS estimate?

Bioextrax AB’s EPS estimate is -0.09.

How many shares outstanding does Bioextrax AB have?

Bioextrax AB has 47,601,730 shares outstanding.

What happened to Bioextrax AB’s price movement after its last earnings report?

Bioextrax AB reported an EPS of -kr0.09 in its last earnings report, beating expectations of -kr0.1. Following the earnings report the stock price went up 11.2%.

Which hedge fund is a major shareholder of Bioextrax AB?

Currently, no hedge funds are holding shares in SE:BIOEX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Bioextrax AB

Bioextrax AB (publ) focuses on developing and commercializing a groundbreaking, biology-driven extraction system. This advanced technology facilitates the recovery of a variety of valuable materials from bacterial origins, such as bioplastic granules (PHA), organic hydrolyzed proteins, keratin fibers, different bio-oils, protein-rich co-products, and amino acids. The firm was founded in 2014 and conducts its operations from Lund, Sweden.